二甲双胍用于妊娠期2型糖尿病女性(MiTy):一项多中心、国际、随机、安慰剂对照试验
该研究在加拿大25个中心和澳大利亚4个中心纳入502例妊娠期2型糖尿病女性,随机接受二甲双胍1000 mg每日两次或安慰剂(均加用胰岛素)。两组主要新生儿复合结局无显著差异(40% vs 40%;RR 1.02 [0.83-1.26];p=0.86);二甲双胍组血糖控制更好、胰岛素用量更少、体重增加更少、剖宫产更少,但小于胎龄儿比例更高(13% vs 7%;RR 1.96 [1.10-3.64])。
要点
- 二甲双胍组与安慰剂组主要新生儿复合结局无显著差异(40% vs 40%;RR 1.02 [0.83-1.26];p=0.86)。
- 二甲双胍组HbA1c更低(41.0 mmol/mol vs 43.2 mmol/mol;p=0.015),胰岛素用量更少(1.1 vs 1.5 units/kg/天;p<0.0001)。
- 二甲双胍组小于胎龄儿比例更高(13% vs 7%;RR 1.96 [1.10-3.64];p=0.026)。
核心结论
- 二甲双胍组在母体血糖控制和新生儿脂肪量方面有获益,但小于胎龄儿比例更高;理解这些效应的影响对指导妊娠期使用二甲双胍很重要。
研究设计与样本
- 前瞻性、多中心、国际、随机、平行、双盲、安慰剂对照试验,在加拿大25个中心和澳大利亚4个中心进行。
- 共随机分配502例妊娠期2型糖尿病女性,253例(50%)接受二甲双胍1000 mg每日两次,249例(50%)接受安慰剂,均加用胰岛素。
- 随机化通过基于网络的计算机随机化服务进行,按中心和孕前BMI(<30 kg/m2或≥30 kg/m2)分层,使用4和6的随机区组大小,比例1:1。
- 纳入标准为2型糖尿病、使用胰岛素、单胎活胎妊娠、孕6周至22周加6天之间。
- 主要结局为胎儿和新生儿复合结局,采用意向性治疗分析,使用对数二项回归模型计算相对风险(RR)和95%CI,按中心和BMI分层。
主要发现
- 主要新生儿复合结局两组无显著差异(40% vs 40%;p=0.86;RR 1.02 [0.83-1.26])。
- 二甲双胍组孕34周HbA1c为41.0 mmol/mol(SD 8.5)vs 安慰剂组43.2 mmol/mol(SD 10)(5.90% vs 6.10%;p=0.015);平均血糖6.05 [0.93] vs 6.27 [0.90],差值-0.2 [-0.4至0.0]。
- 二甲双胍组胰岛素用量更少(1.1 units/kg/天 vs 1.5 units/kg/天;差值-0.4 [95% CI -0.5至-0.2];p<0.0001),体重增加更少(7.2 kg vs 9.0 kg;差值-1.8 [-2.7至-0.9];p<0.0001),剖宫产更少(125/234 [53%] vs 148/236 [63%];RR 0.85 [95% CI 0.73-0.99];p=0.031)。
- 两组妊娠期高血压疾病无显著差异(55/23% vs 56/23%;p=0.93;RR 0.99 [0.72-1.35]),脐带C肽无显著差异(673 pmol/L [435] vs 758 pmol/L [595];p=0.10;均值比0.88 [0.72-1.02])。
- 二甲双胍暴露婴儿出生体重更低(平均3156 g [SD 742] vs 3375 g [742];差值-218 [-353至-82];p=0.002),大于第97百分位者更少(20/9% vs 34/15%;RR 0.58 [0.34-0.97];p=0.041),出生体重≥4000 g者更少(28/12% vs 44/19%;RR 0.65 [0.43-0.99];p=0.046),脂肪测量更低(皮褶厚度总和16.0 mm [SD 5.0] vs 17.4 [6.2] mm;差值-1.41 [-2.6至-0.2];p=0.024;新生儿脂肪量13.2 [SD 6.2] vs 14.6 [5.0];p=0.017)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although metformin is increasingly being used in women with type 2 diabetes during pregnancy, little data exist on the benefits and harms of metformin use on pregnancy outcomes in these women. We aimed to investigate the effects of the addition of metformin to a standard regimen of insulin on neonatal morbidity and mortality in pregnant women with type 2 diabetes. METHODS: In this prospective, multicentre, international, randomised, parallel, double-masked, placebo-controlled trial, women with type 2 diabetes during pregnancy were randomly assigned from 25 centres in Canada and four in Australia to receive either metformin 1000 mg twice daily or placebo, added to insulin. Randomisation was done via a web-based computerised randomisation service and stratified by centre and pre-pregnancy BMI (<30 kg/m2 or ≥30 kg/m2) in a ratio of 1:1 using random block sizes of 4 and 6. Women were eligible if they had type 2 diabetes, were on insulin, had a singleton viable pregnancy, and were between 6 and 22 weeks plus 6 days' gestation. Participants were asked to check their fasting blood glucose level before the first meal of the day, before the last meal of the day, and 2 h after each meal. Insulin doses were adjusted aiming for identical glucose targets (fasting glucose <5·3 mmol/L [95 mg/dL], 2-h postprandial glucose <6·7 mmol/L [120 mg/dL]). Study visits were done monthly and patients were seen every 1-4 weeks as was needed for standard clinical care. At study visits blood pressure and bodyweight were measured; patients were asked about tolerance to their pills, any hospitalisations, insulin doses, and severe hypoglycaemia events; and glucometer readings were downloaded to the central coordinating centre. Participants, caregivers, and outcome assessors were masked to the intervention. The primary outcome was a composite of fetal and neonatal outcomes, for which we calculated the relative risk and 95% CI between groups, stratifying by site and BMI using a log-binomial regression model with an intention-to-treat analysis. Secondary outcomes included several relevant maternal and neonatal outcomes. The trial was registered with ClinicalTrials.gov, NCT01353391. FINDINGS: Between May 25, 2011, and Oct 11, 2018, we randomly assigned 502 women, 253 (50%) to metformin and 249 (50%) to placebo. Complete data were available for 233 (92%) participants in the metformin group and 240 (96%) in the placebo group for the primary outcome. We found no significant difference in the primary composite neonatal outcome between the two groups (40% vs 40%; p=0·86; relative risk [RR] 1·02 [0·83 to 1·26]). Compared with women in the placebo group, metformin-treated women achieved better glycaemic control (HbA1c at 34 weeks' gestation 41·0 mmol/mol [SD 8·5] vs 43·2 mmol/mol [-10]; 5·90% vs 6·10%; p=0·015; mean glucose 6·05 [0·93] vs 6·27 [0·90]; difference -0·2 [-0·4 to 0·0]), required less insulin (1·1 units per kg per day vs 1·5 units per kg per day; difference -0·4 [95% CI -0·5 to -0·2]; p<0·0001), gained less weight (7·2 kg vs 9·0 kg; difference -1·8 [-2·7 to -0·9]; p<0·0001) and had fewer caesarean births (125 [53%] of 234 in the metformin group vs 148 [63%] of 236 in the placebo group; relative risk [RR] 0·85 [95% CI 0·73 to 0·99]; p=0·031). We found no significant difference between the groups in hypertensive disorders (55 [23%] in the metformin group vs 56 [23%] in the placebo group; p=0·93; RR 0·99 [0·72 to 1·35]). Compared with those in the placebo group, metformin-exposed infants weighed less (mean birthweight 3156 g [SD 742] vs 3375 g [742]; difference -218 [-353 to -82]; p=0·002), fewer were above the 97th centile for birthweight (20 [9%] in the metformin group vs 34 [15%] in the placebo group; RR 0·58 [0·34 to 0·97]; p=0·041), fewer weighed 4000 g or more at birth (28 [12%] in the metformin group vs 44 [19%] in the placebo group; RR 0·65 [0·43 to 0·99]; p=0·046), and metformin-exposed infants had reduced adiposity measures (mean sum of skinfolds 16·0 mm [SD 5·0] vs 17·4 [6·2] mm; difference -1·41 [-2·6 to -0·2]; p=0·024; mean neonatal fat mass 13·2 [SD 6·2] vs 14·6 [5·0]; p=0·017). 30 (13%) infants in the metformin group and 15 (7%) in the placebo group were small for gestational age (RR 1·96 [1·10 to 3·64]; p=0·026). We found no significant difference in the cord c-peptide between groups (673 pmol/L [435] in the metformin group vs 758 pmol/L [595] in the placebo group; p=0·10; ratio of means 0·88 [0·72 to 1·02]). The most common adverse event reported was gastrointestinal (38 events in the metformin group and 38 events in the placebo group). INTERPRETATION: We found several maternal glycaemic and neonatal adiposity benefits in the metformin group. Along with reduced maternal weight gain and insulin dosage and improved glycaemic control, the lower adiposity and infant size measurements resulted in fewer large infants but a higher proportion of small-for-gestational-age infants. Understanding the implications of these effects on infants will be important to properly advise patients who are contemplating the use of metformin during pregnancy. FUNDING: Canadian Institutes of Health Research, Lunenfeld-Tanenbaum Research Institute, University of Toronto.
引用
- Feig DS, Donovan LE, Zinman B, et al. Metformin in women with type 2 diabetes in pregnancy (MiTy): a multicentre, international, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2020. PMID: 32946820. doi:10.1016/S2213-8587(20)30310-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。